{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:59:17Z","timestamp":1767830357814,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:00:00Z","timestamp":1614297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COVID-19 pandemic continues to rage on, and clinical research has been promoted worldwide. We aimed to assess the clinical and methodological characteristics of treatment clinical trials that have been set forth as an early response to the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>First, we reviewed all registered clinical trials on COVID-19. The World Health Organization International Trials Registry Platform and national trial registries were searched for COVID-19 trials through April 19th, 2020. For each record, independent researchers extracted interventions, participants, and methodological characteristics.<\/jats:p>\n                <jats:p>Second, on September 14th, 2020 we evaluated the recruitment status and availability of the results of COVID-19 treatment trials previously identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In April 2020, a total of 580 trials evaluating COVID-19 treatment were registered. Reporting quality was poor (core participant information was missing in 24.1 to 92.7%). Between 54.0 and 93.8% of the trials did not plan to include older people or those with a higher baseline risk. Most studies were randomised (67.9%), single-centre (58.3%), non-industry-funded (81.1%), to be conducted in China (47.6%), with a median duration of 184\u2009days and a median sample size of 100 participants. Core endpoints (mortality, clinical status, and hospitalization length) were planned to be assessed in 5.2 to 13.1% of the trials. Five months later, 66 trials (11.4%) were reported as \u201cCompleted\u201d, and only 46 (7.9%) had public results available. One hundred forty-four of 580 trials (24.8%) either had the status \u201cNot yet recruiting\u201d or \u201cSuspended\u201d, and 18 (3.1%) trials were prematurely stopped (\u201cTerminated\u201d or \u201cWithdrawn\u201d) The number of completed trials and trials with results are much lower than anticipated, considering the planned follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results raise concerns about the success of the initial global research effort on COVID-19 treatment. The clinical and methodological characteristics of early COVID-19 treatment trials limit their capability to produce clear answers to critical questions in the shortest possible time.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-021-01233-w","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:03:39Z","timestamp":1614344619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities"],"prefix":"10.1186","volume":"21","author":[{"given":"Beatrice","family":"Mainoli","sequence":"first","affiliation":[]},{"given":"Tiago","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Gon\u00e7alo S.","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Lu\u00edsa","family":"Prada","sequence":"additional","affiliation":[]},{"given":"Nilza","family":"Gon\u00e7alves","sequence":"additional","affiliation":[]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-4921","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"issue":"10223","key":"1233_CR1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet"},{"issue":"9","key":"1233_CR2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/CM9.0000000000000744","volume":"133","author":"L Kui","year":"2020","unstructured":"Kui L, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, Xiao W, Wang Y-N, Zhong M-H, Li C-H. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025.","journal-title":"Chin Med J"},{"key":"1233_CR3","doi-asserted-by":"publisher","first-page":"k5094","DOI":"10.1136\/bmj.k5094","volume":"363","author":"RW Yeh","year":"2018","unstructured":"Yeh RW, Valsdottir LR, Yeh MW, Shen C, Kramer DB, Strom JB, Secemsky EA, Healy JL, Domeier RM, Kazi DS. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. bmj. 2018;363:k5094.","journal-title":"bmj"},{"issue":"1","key":"1233_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s12874-020-01047-2","volume":"20","author":"M Fidahic","year":"2020","unstructured":"Fidahic M, Nujic D, Runjic R, Civljak M, Markotic F, Lovric Makaric Z, Puljak L. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19. BMC Med Res Methodol. 2020;20(1):161.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"1233_CR5","doi-asserted-by":"publisher","first-page":"e039978","DOI":"10.1136\/bmjopen-2020-039978","volume":"10","author":"HB Mehta","year":"2020","unstructured":"Mehta HB, Ehrhardt S, Moore TJ, Segal JB, Alexander GC. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. BMJ Open. 2020;10(6):e039978.","journal-title":"BMJ Open"},{"key":"1233_CR6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/1745-6215-15-428","volume":"15","author":"D Ogino","year":"2014","unstructured":"Ogino D, Takahashi K, Sato H. Characteristics of clinical trial websites: information distribution between ClinicalTrials.gov and 13 primary registries in the WHO registry network. Trials. 2014;15:428.","journal-title":"Trials"},{"key":"1233_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13063-016-1310-8","volume":"17","author":"SL Harriman","year":"2016","unstructured":"Harriman SL, Patel J. When are clinical trials registered? An analysis of prospective versus retrospective registration. Trials. 2016;17:187.","journal-title":"Trials"},{"key":"1233_CR8","unstructured":"WHO\u2019s Global research on coronavirus disease (COVID-19) Database [https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov]."},{"key":"1233_CR9","unstructured":"Cochrane COVID-19 Study Register."},{"key":"1233_CR10","doi-asserted-by":"publisher","first-page":"m2980","DOI":"10.1136\/bmj.m2980","volume":"370","author":"RA Siemieniuk","year":"2020","unstructured":"Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, Pardo-Hernandez H, Rochwerg B, Lamontagne F, Han MA, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. Bmj. 2020;370:m2980.","journal-title":"Bmj"},{"issue":"7","key":"1233_CR11","first-page":"Cd013600","volume":"7","author":"V Piechotta","year":"2020","unstructured":"Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, Lamikanra A, Kimber C, McQuilten Z, So-Osman C, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7(7):Cd013600.","journal-title":"Cochrane Database Syst Rev"},{"key":"1233_CR12","unstructured":"Oxford COVID-19 Evidence Service [https:\/\/www.cebm.net\/covid-19\/global-covid-19-case-fatality-rates\/]."},{"key":"1233_CR13","unstructured":"Worldometers Coronavirus cases [https:\/\/www.worldometers.info\/coronavirus\/coronavirus-cases\/]."},{"issue":"2","key":"1233_CR14","first-page":"00227","volume":"5","author":"N Gobat","year":"2019","unstructured":"Gobat N, Amuasi J, Yazdanpanah Y, Sigfid L, Davies H, Byrne J-P, Carson G, Butler C, Nichol A, Goossens H. Advancing preparedness for clinical research during infectious disease epidemics. Eur Respiratory Soc. 2019;5(2):00227.","journal-title":"Eur Respiratory Soc"},{"issue":"1","key":"1233_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","volume":"16","author":"P Pallmann","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, Holmes J, Mander AP, Sydes MR, Villar SS. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.","journal-title":"BMC Med"},{"issue":"1","key":"1233_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375(1):65\u201374.","journal-title":"N Engl J Med"},{"key":"1233_CR17","doi-asserted-by":"crossref","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. 2020.","DOI":"10.1101\/2020.06.22.20137273"},{"issue":"21","key":"1233_CR18","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","volume":"383","author":"P Horby","year":"2020","unstructured":"Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, et al. Effect of Hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383(21):2030.","journal-title":"N Engl J Med"},{"key":"1233_CR19","doi-asserted-by":"crossref","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020.","DOI":"10.1056\/NEJMoa2007764"},{"key":"1233_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1371\/journal.pone.0203387","volume":"13","author":"M Brueckner","year":"2018","unstructured":"Brueckner M, Titman A, Jaki T, Rojek A, Horby P. Performance of different clinical trial designs to evaluate treatments during an epidemic. PLoS One. 2018;13:9.","journal-title":"PLoS One"},{"issue":"11","key":"1233_CR21","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jclinepi.2013.05.016","volume":"66","author":"S Unverzagt","year":"2013","unstructured":"Unverzagt S, Prondzinsky R, Peinemann F. Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. J Clin Epidemiol. 2013;66(11):1271\u201380.","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1233_CR22","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1097\/CCM.0b013e3181bc7bd5","volume":"37","author":"R Bellomo","year":"2009","unstructured":"Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37(12):3114\u20139.","journal-title":"Crit Care Med"},{"issue":"4","key":"1233_CR23","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1097\/CCM.0b013e318168ea3e","volume":"36","author":"GA Ospina-Tasc\u00f3n","year":"2008","unstructured":"Ospina-Tasc\u00f3n GA, B\u00fcchele GL, Vincent J-L. Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med. 2008;36(4):1311\u201322.","journal-title":"Crit Care Med"},{"issue":"5","key":"1233_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1365-2125.2005.02435.x","volume":"59","author":"JK Aronson","year":"2005","unstructured":"Aronson JK. Biomarkers and surrogate endpoints. Br J Clin Pharmacol. 2005;59(5):491\u20134.","journal-title":"Br J Clin Pharmacol"},{"key":"1233_CR25","unstructured":"Core outcome set developers\u2019 response to COVID-19 (7th July 2020) [https:\/\/www.comet-initiative.org\/Studies\/Details\/1538]."},{"issue":"11","key":"1233_CR26","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0895-4356(00)00242-0","volume":"53","author":"JA Sterne","year":"2000","unstructured":"Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119\u201329.","journal-title":"J Clin Epidemiol"},{"issue":"10236","key":"1233_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569.","journal-title":"Lancet"},{"key":"1233_CR28","doi-asserted-by":"crossref","unstructured":"Woodhead M: 80% of China\u2019s clinical trial data are fraudulent, investigation finds. In.: British medical journal publishing Group; 2016.","DOI":"10.1136\/bmj.i5396"},{"key":"1233_CR29","unstructured":"Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments [https:\/\/www.ema.europa.eu\/en\/news\/call-pool-research-resources-large-multi-centre-multi-arm-clinical-trials-generate-sound-evidence]."},{"issue":"7","key":"1233_CR30","first-page":"674","volume":"382","author":"R Collins","year":"2020","unstructured":"Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. Mass Medical Soc. 2020;382(7):674.","journal-title":"Mass Medical Soc"},{"issue":"5","key":"1233_CR31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1056\/NEJMra1614394","volume":"377","author":"TR Frieden","year":"2017","unstructured":"Frieden TR. Evidence for health decision making\u2014beyond randomized, controlled trials. N Engl J Med. 2017;377(5):465\u201375.","journal-title":"N Engl J Med"},{"issue":"14","key":"1233_CR32","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1056\/NEJMsb1905390","volume":"382","author":"NE Dean","year":"2020","unstructured":"Dean NE, Gsell PS, Brookmeyer R, Crawford FW, Donnelly CA, Ellenberg SS, Fleming TR, Halloran ME, Horby P, Jaki T, et al. Creating a framework for conducting randomized clinical trials during disease outbreaks. N Engl J Med. 2020;382(14):1366\u20139.","journal-title":"N Engl J Med"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-021-01233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12874-021-01233-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-021-01233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T13:06:30Z","timestamp":1614344790000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-021-01233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,26]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1186\/s12874-021-01233-w","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,26]]},"assertion":[{"value":"9 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Joaquim J Ferreira received speaker and consultant fees from GlaxoSmithKline, Novartis, TEVA, Lundbeck, Solvay, Abbott, Bial, Merck-Serono, Grunenthal and Merck Sharp and Dohme. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}